- Qurgen announced that the Company had successfully completed its Series A financing totaling US$12 million between October 2017 and May 2019. The round attracted participation from a number of internationally renowned investment institutions. The proceeds will be mainly used to advance the IND clinical applications of the Company’s core protein-based anti-cancer drugs, expand its R&D pipeline, and further strengthen Qurgen’s technological leadership in the global regenerative medicine sector.
- During the Series A financing process, Qurgen achieved a number of key R&D milestones. The Company’s self-developed broad-spectrum anti-cancer protein drug for the treatment of advanced triple-negative breast cancer, glioma and pancreatic cancer has successfully entered the final stage of preclinical research. At the same time, Qurgen has actively promoted communication and application procedures with regulatory authorities in both China and the United States, planning to formally submit Investigational New Drug (IND) applications to the U.S. FDA and China’s CFDA between the end of 2018 and the first half of 2019.
- Qurgen will continue to uphold its mission of saving human lives and improving human health, leading the industrial development of global stem cell and regenerative medicine, and bringing more innovative and high-quality regenerative medicine products to patients worldwide.
